Panelists Hope S. Rugo, MD; Adam M. Brufsky, MD, PhD; Michael Gnant, MD; Michael Untch, MD; and Joyce A. O’Shaughnessy, MD, review the progress to date in developing PI3-kinase inhibitors for patients with hormone-driven metastatic breast cancer, as well as the results of the LORELEI trial of neoadjuvant letrozole and taselisib.

свернуть